DAWN General Counsel reports RSU settlements and stock sale
Rhea-AI Filing Summary
Day One Biopharmaceuticals (DAWN) reported insider equity activity by its General Counsel & Secretary. On November 15, 2025, several blocks of Restricted Stock Units (RSUs) were settled, delivering 2,963, 1,750, and two blocks of 3,687 shares of common stock, each RSU converting into one share for no cash consideration. The RSUs vest over time based on continued service, with portions vesting on specified quarterly dates.
On November 17, 2025, the insider sold 4,319 shares of common stock at a weighted average price of $8.9147 per share, solely to cover tax liabilities related to the RSU settlements. After these transactions, the insider beneficially owned 62,626 shares of Day One common stock directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 4,319 | $8.9147 | $39K |
| Exercise | Restricted Stock Unit (RSU) | 2,963 | $0.00 | -- |
| Exercise | Restricted Stock Unit (RSU) | 1,750 | $0.00 | -- |
| Exercise | Restricted Stock Unit (RSU) | 3,687 | $0.00 | -- |
| Exercise | Restricted Stock Unit (RSU) | 3,687 | $0.00 | -- |
| Exercise | Common Stock | 2,963 | $0.00 | -- |
| Exercise | Common Stock | 1,750 | $0.00 | -- |
| Exercise | Common Stock | 3,687 | $0.00 | -- |
| Exercise | Common Stock | 3,687 | $0.00 | -- |
Footnotes (1)
- Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $8.545 to $9.305, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade. The RSUs vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vest in quarterly installments thereafter on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. RSUs do not expire; they either vest or are canceled prior to the vesting date. The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
FAQ
What insider transaction did Day One Biopharmaceuticals (DAWN) report?
Day One Biopharmaceuticals reported that its General Counsel & Secretary settled multiple blocks of Restricted Stock Units (RSUs) into common stock and then sold 4,319 shares to cover tax liabilities arising from those RSU settlements.
What are RSUs in the context of Day One (DAWN) insider compensation?
Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Day One common stock upon settlement for no consideration, subject to time-based vesting and the insider’s continued service to the company.
What is the vesting schedule for the reported Day One (DAWN) RSUs?
One RSU award vests as to 25% of the total on November 15, 2023, with the remaining amount vesting in equal quarterly installments on February 15, May 15, August 15, and November 15, contingent on continued service. Another RSU grant vests as to 1/16th of the total award on the same quarterly dates, also subject to continued service.
Do the Day One (DAWN) RSUs expire if they do not vest?
The disclosure notes that RSUs do not expire; they either vest according to the schedule or are canceled prior to the vesting date if vesting conditions, such as continued service, are not satisfied.